Gennex Laboratories Ltd

Consolidated Q1 FY27

• Consolidated Revenue from Operations: Rs 3,984.17 lakh.
• Consolidated Total Income: Rs 4,184.99 lakh.
• Consolidated Net Profit after Tax: Rs 466.64 lakh.
• Consolidated PBT: Rs 491.64 lakh.
• Consolidated EPS: Rs 0.163 (basic/diluted).
• Consolidated tax expense: Rs 25.00 lakh.
• Segment: Bulk Drugs, Biotech Products & Intermediates.

Standalone Q1 FY27

• Standalone Revenue from Operations: Rs 3,467.79 lakh.
• Standalone Total Income: Rs 3,667.49 lakh.
• Standalone Net Profit after Tax: Rs 395.53 lakh.
• Standalone EPS: Rs 0.163.

Geography & Segment

• Single reportable segment: Bulk Drugs, Biotech Products and Intermediates.
• India quarterly revenue: Rs 2,537.08 lakh.
• Colombia quarterly revenue: Rs 350.60 lakh.
• Egypt quarterly revenue: Rs 253.58 lakh.
• Vietnam quarterly revenue: Rs 81.72 lakh.
• Mexico quarterly revenue: Rs 37.65 lakh.
• Total quarterly revenue by country: Rs 3,467.79 lakh.

Board actions & notes

• Board approved unaudited standalone and consolidated results for quarter ended 30 Jun 2026.
• Limited review reports by statutory auditors on standalone and consolidated results.
• One reportable segment; prior periods regrouped.
• Subsidiary Deccan Remedies Ltd included in consolidated results.

Meeting Details

• Meeting date: August 14, 2026.
• Meeting time: 04:00 PM.
• Venue: Corporate Office of the Company.

Key Agenda Items

• Consider and adopt Unaudited Standalone and Consolidated Financial Statements for quarter ended June 30, 2026.
• Consider Limited Review Reports on Standalone and Consolidated Financial Statements for quarter ended June 30, 2026.
• Other Business items.

Other Notes

• Trading window closed from July 01, 2026; opens 48 hours after unaudited results declaration.

Dematerialisation processing status

• Dematerialisation requests received were confirmed to depositories; dematerialised securities listed on exchanges.
• Physical dematerialisation certificates mutilated and cancelled; depository name substituted as registered owner within 15 days.

EGM purpose

• Approve appointment of Ms. Khushbu Kachhawa as Non-Executive Independent Woman Director.

Resolution

• Special resolution: regularize Ms. Khushbu Kachhawa's appointment as Independent Director.
• Term runs from 14 February 2026 until conclusion of the 45th AGM in 2030.
• She was appointed earlier as additional director after Ms. Shilpa Bung resigned.
• Ms. Kachhawa holds no company shares and has no relationship with directors or KMPs.
• She is eligible for sitting fees for board and committee meetings.

Board impact

• Appointment fills the woman director vacancy and strengthens board independence.
• No change in shareholding, capital structure, or control is disclosed.

Director profile

• Ms. Kachhawa has about five years' experience in corporate affairs and secretarial matters.
• She is a director and committee member at Snehaa Organics Limited.